Summer Sizemore Davidson

Residency trained PharmD via @ugapharmacy, @erlangerrx, and @emoryhealthcare. Opinions are my own.

[Summer Sizemore Davidson @summerasize]

Proud to be part of Shionogi Inc. (U.S.) and deliver the first and only FDA-approved oral option to help prevent COVID-19 following exposure. Learn more about today’s U.S. FDA approval: https://t.co/YJxvwqEmbg

[Shionogi Inc. (U.S.) @ShionogiUS]

#News: The FDA has approved our oral antiviral for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older. It is the first and only oral option to help prevent COVID-19 following exposure to an infected individual. Learn more here: https://t.co/rc8mjA43zX

[Shionogi Inc. (U.S.) @ShionogiUS]

#BREAKINGNEWS: @NEJM has published results from our SCORPIO-PEP clinical trial, the first and only Phase 3 study of an investigational oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure to an infected individual. #InfectiousDisease #COVID19

Learn more: https://t.co/K27S4wNarf

[IDSA @IDSAInfo]

The removal of #HIV- and #LGBTQ-related resources from the websites of the @CDCgov and other health agencies is deeply concerning.

Access to this information is crucial for ID and HIV health care professionals.

Our full statement: https://t.co/xcqdZ6515p

[Summer Sizemore Davidson @summerasize]

Exciting new publication from @BioPortoDx!

[BioPortoDx @BioPortoDx]

Presenting the largest study to date establishing uNGAL reference intervals for 3 months to > 65 years old. Establishing reference ranges of uNGAL lays a strong foundation for clinicians to evaluate the test across different age ranges. https://t.co/n3uWvhJnk1

[BioPortoDx @BioPortoDx]

🥳📣The first patient in our US study of ProNephro AKI (NGAL) for adult use has been enrolled at Mass General Hospital. This study will determine a cut-off for risk stratification of moderate to severe AKI in adults and will be followed by a validation study. 👏👏👇

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔥BALANCE RCT🔥
74 hospitals in 7 countries
3,608 patients
A 7-day course of antibiotics for hospitalized patients with bloodstream infections was non inferior to 14d within a 4% prespecified margin for mortality at 90 days @BradSpellberg @DrToddLee
https://t.co/WhH6ThSW3Z

[Summer Sizemore Davidson @summerasize]

Great info this past week at #KidneyWk bringing awareness to AKI and highlighting that more work needs to be done around serum creatinine #BioPortoMedSci @BioPortoDx

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

SCr remains the primary clinical biomarker for monitoring of kidney function. It plays a critical role in the detection of AKI & dose adjustments for renally cleared meds, esp Abx; however, SC is neither sensitive nor specific for the early detection of acute decreases in GFR.

[BioPortoDx @BioPortoDx]

Dr. Allegretti named PI and @ProPharma selected as CRO for the first of two studies in our upcoming Adult AKI Clinical Study. The first study will enroll US patients with the goal of determining a cut-off point for severe #AKI risk stratification in adults. #ICU #clinicaltrials

[BioPortoDx @BioPortoDx]

Attending #KidneyWk? There are so many great sessions, but this is one of our favorites.👇Will we see you there?
🎯Neonatal and Pediatric AKI: Advances in Prediction and Treatment @PrasadDeva64 @the_kidney_dude @mcstarr1 @menonshina
🗓️Oct 25
⏰10:30-12:30 PDT
📍Room 33

[BioPortoDx @BioPortoDx]

Today we celebrate all the #PharmDs who serve as experts to prevent drug-induced #AKI in the #ICU. Including a #pharmacist on your ICU team reduces AKI incidence and improves therapeutic outcomes. PMID: 36394173 #WorldPharmistsDay2024
@SCCM_CPP @BPSweb @ASHPOfficial

[CDC @CDCgov]

CDC recommends everyone 6 months and older get the 2024-2025 COVID-19 vaccine to protect against severe COVID-19 illness, hospitalization, and death. Read the latest on CDC’s 2024-2025 COVID-19 vaccine recommendation in @CDCMMWR: https://t.co/2ZFeTDxGmK

[Summer Sizemore Davidson @summerasize]

@DocWoc71 @kaj401 @oncopharmacist @DrRossanaRosa @mmPharmD @ErinMcCreary @idpharmd @SIDPharm 🥰 @DocWoc71 thank you!!!

[Summer Sizemore Davidson @summerasize]

@HelenPharmD @dosyn_zosyn @Sarah_mch Omg 😭😭 too many good ones to pick

[Helen Ding @HelenPharmD]

My coworker @dosyn_zosyn received this gem from his student today. This may be the most iconic thing to have happened in ID pharmacy history!!! Which one is your fave?

Creds: @sarah_mch

[AJHP @AJHPOfficial]

A pharmacist-driven deprescribing protocol for negative urine and sexually transmitted infection cultures in the emergency department increases antibiotic-free days. https://t.co/o34eK596Xw

[Mark Lewis, MD, FASCO @marklewismd]

Gram positive

[Helen Ding @HelenPharmD]

‼️Did you know that susceptibilities for many PO cephalosporins are inferred from cefazolin, not ceftriaxone? May overcall resistance but safest option if unable to test directly.

Removed cefdinir from our adult formulary and switched to cefuroxime. Here’s why! #downwithcefdinir

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔆TMP/SMX was universally susceptible against clinical isolates of β-hemolytic Streptococcus using the gold standard BMD
🔆TMP/SMX is a potential monotherapy agent for the treatment of β-hemolytic Streptococcus SSTIs while clinda & esp doxy may be less reliable empiric options

[Takahiro Matsuo (Taka), MD @TakaMatsuo_ID]

First At-Home Test for Chlamydia and Gonorrhea Receives FDA Approval!

👉People can obtain the direct-to-consumer Simple Test over the counter without a prescription!

https://t.co/FaMxmKlmkX